Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group. Arribas JR, et al. Among authors: crespo m. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062880 Clinical Trial.
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
Burgos J, Crespo M, Falcó V, Curran A, Navarro J, Imaz A, Domingo P, Podzamczer D, Mateo MG, Villar S, Van den Eynde E, Ribera E, Pahissa A. Burgos J, et al. Among authors: crespo m. J Antimicrob Chemother. 2012 Oct;67(10):2479-86. doi: 10.1093/jac/dks227. Epub 2012 Jun 22. J Antimicrob Chemother. 2012. PMID: 22729925
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martínez E, Fernández I, Knobel H, Podzamczer D, Iribarren JA, Peñaranda M, Crespo M; PIMOCS Study Group. Curran A, et al. Among authors: crespo m. J Antimicrob Chemother. 2014 May;69(5):1390-6. doi: 10.1093/jac/dkt517. Epub 2014 Jan 10. J Antimicrob Chemother. 2014. PMID: 24415645
Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la Torre J, Tuset M, Gatell JM. Rivero A, et al. Among authors: crespo m. Enferm Infecc Microbiol Clin. 2017 Feb;35(2):88-99. doi: 10.1016/j.eimc.2016.06.013. Epub 2016 Jul 25. Enferm Infecc Microbiol Clin. 2017. PMID: 27459919 Free article.
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Curran A, Martinez E, Podzamczer D, Lonca M, Barragan P, Crespo M, Falco V, Vidal-Sicart S, Imaz A, Martinez M, Gatell JM, Ribera E. Curran A, et al. Among authors: crespo m. Antivir Ther. 2012;17(4):711-8. doi: 10.3851/IMP2081. Epub 2012 Feb 28. Antivir Ther. 2012. PMID: 22374987 Clinical Trial.
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. AIDS Res Ther. 2020 Jul 20;17(1):45. doi: 10.1186/s12981-020-00302-2. AIDS Res Ther. 2020. PMID: 32690099 Free PMC article.
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S; Spanish HIV Research Network (CoRIS). Serrano-Villar S, et al. Lancet HIV. 2020 Aug;7(8):e565-e573. doi: 10.1016/S2352-3018(20)30202-2. Lancet HIV. 2020. PMID: 32763219 Clinical Trial.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM. Rivero A, et al. Among authors: crespo m. Enferm Infecc Microbiol Clin (Engl Ed). 2018 May;36(5):268-276. doi: 10.1016/j.eimc.2017.04.002. Epub 2017 May 19. Enferm Infecc Microbiol Clin (Engl Ed). 2018. PMID: 28532596 English, Spanish.
1,272 results